What is Valkee?
Headquartered in Oulu, Finland, Valkee operates at the intersection of health technology and neuroscience. Since its inception in 2007, the company has leveraged rigorous academic partnerships, specifically with Oulu University, to develop proprietary bright light headsets. By targeting the brain's light-sensitive pathways, Valkee addresses conditions such as seasonal affective disorder and jet lag. With a proven clinical track record—demonstrating efficacy in nine out of ten participants—the company has successfully scaled its operations across more than 20 countries, establishing a robust user base that reports high satisfaction and recommendation rates.
How much funding has Valkee raised?
Valkee has raised a total of $9.7M across 1 funding round:
Series A
$9.7M
Series A (2013): $9.7M, investors not publicly disclosed
Key Investors in Valkee
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Valkee?
With this major enterprise-level funding, Valkee is positioned to transition from a niche wellness provider to a broader player in the cognitive and physical performance sector. The strategic roadmap includes expanding clinical research to validate the efficacy of bright light therapy in new performance-enhancing applications. As the company scales, it will likely focus on deepening its distribution networks and refining its hardware to meet the demands of a growing international market, ensuring that its evidence-based solutions remain at the forefront of the health-tech industry.
See full Valkee company page
